Ivermectin 1% | Metronidazole 1% | Niacinamide 3%
Ivermectin 1% | Metronidazole 1% | Niacinamide 3% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
Ivermectin 1% | Metronidazole 1% | Niacinamide 3% is a compounded topical three-ingredient cream combining complementary anti-inflammatory, antiparasitic, and barrier-repair agents for prescriber-directed management of papulopustular rosacea. This formulation targets the key pathogenic drivers of rosacea — Demodex-triggered inflammation, bacterial dysbiosis/oxidative inflammation, and skin barrier dysfunction — without a dedicated depigmenting component. Genesis Compounding prepares this as a prescription-only, patient-specific, 503A compounded preparation not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Ivermectin 1% | Avermectin antiparasitic that eradicates Demodex mites via GABA-agonist/glutamate-gated chloride channel activation; also directly inhibits pro-inflammatory cytokine release (TNF-α, IL-1β) in skin. |
| Metronidazole 1% | Nitroimidazole with bacteriostatic and anti-inflammatory activity: suppresses neutrophil oxidative burst and ROS production at inflammatory rosacea sites, reducing erythema and papulopustular lesions. |
| Niacinamide 3% | Vitamin B3 that reduces skin barrier disruption (by stimulating ceramide synthesis), inhibits melanin transfer, and provides anti-inflammatory cytokine suppression to reduce rosacea-associated erythema and irritation. |
Route: Topical. Apply a thin layer to the entire affected facial area once to twice daily as directed by the prescriber. Avoid eyes and mucous membranes. Gentle application technique is recommended on inflamed rosacea skin.
Dosing is prescriber-determined:
- Once to twice daily topical application to affected facial areas.
- Rosacea management is often long-term; prescriber determines duration and adjunctive therapies.
- Clinical improvement is expected at 8–12 weeks of consistent use.
- Ivermectin 1%: Activates glutamate-gated chloride channels and GABA receptors in Demodex mite neurons, causing mite paralysis and death; simultaneously inhibits NF-κB/MAPK-driven cytokine production in human keratinocytes, reducing the mite-triggered inflammatory cascade.
- Metronidazole 1%: Reduced intracellularly to reactive intermediates that are bacteriostatic against anaerobic organisms; more importantly for rosacea, directly inhibits neutrophil oxidative burst, reducing superoxide and H₂O₂ at inflammatory skin sites and downregulating pro-inflammatory mediators.
- Niacinamide 3%: Inhibits melanosome transfer to keratinocytes; enhances ceramide, fatty acid, and natural moisturizing factor synthesis to restore the compromised skin barrier seen in rosacea; suppresses inflammatory cytokines (IL-6, TNF-α) via NAD+-dependent pathways.
This streamlined triple combination is for prescriber-directed management of inflammatory papulopustular rosacea where pigmentation management is not the primary concern. The absence of a dedicated depigmenting agent makes this appropriate for patients with Fitzpatrick types I–III (lower PIH risk) or those in whom pigmentation-specific therapy is handled separately. Rosacea management requires multimodal therapy; this formulation may be used alongside oral doxycycline, laser/light therapy, or other prescriber-directed modalities.
Monitoring: Papule/pustule counts and erythema at 8–12 weeks; skin tolerance; assess for secondary infection if lesions worsen.
Contraindications:
- Known hypersensitivity to any component.
- Metronidazole: caution in first trimester of pregnancy (topical absorption minimal but present).
Warnings & Precautions:
- Avoid periorbital application.
- Topical metronidazole: theoretical disulfiram-like reaction with alcohol (negligible at topical doses).
Drug Interactions:
- Topical concentrations: no clinically significant drug interactions expected.
Common Side Effects: Mild erythema, stinging, burning, or dryness at application site. Generally well-tolerated.
Store at room temperature (15°C–25°C). Keep tightly sealed. Protect from light and heat. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding.
How does this formulation differ from the four-ingredient version with kojic acid?
This formulation omits kojic acid, making it suitable for patients where post-inflammatory hyperpigmentation is not a primary concern. It focuses solely on the anti-inflammatory, antiparasitic, and barrier-repair aspects of rosacea management.
Can ivermectin and metronidazole be used together safely?
Yes. Both are established topical rosacea therapies with complementary, non-overlapping mechanisms. Ivermectin targets Demodex mites and cytokine production; metronidazole targets bacterial anaerobes and neutrophil oxidative activity. Together they provide broader anti-inflammatory coverage.
How long before results are seen?
Significant improvement in papule/pustule counts is typically observed at 12 weeks. Background erythema may improve more gradually. Consistent daily use is required for optimal outcomes.
Is this FDA-approved?
No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not FDA-approved as a compounded drug.
Should I avoid the sun while using this cream?
Yes. UV exposure is a primary rosacea trigger. Daily broad-spectrum sunscreen (SPF ≥30) is strongly recommended throughout treatment.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.